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Abstract
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, 
well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®) has 
been developed and has replaced Vivaglobin® (SCIG 16%).
An observational prospective multi-centric open-label study, with retrospective comparison was conducted in 15 
Italian centers, in order to investigate whether and to what extent switching to Hizentra® would affect frequency of 
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infusions, number of infusion sites, patients’ satisfaction, and tolerability in patients previously treated with Vivaglobin® 
or intravenous immunoglobulins (IVIG).
Any variations of dosage, frequency and duration of the infusions, and of number of infusion sites induced by Hizentra® 
with respect to the former treatment were recorded. Practical advantages and disadvantages of Hizentra®, with respect 
to the medicinal product formerly used, and the variations in patients’ therapy-related satisfaction were monitored 
by means of the TSQM (Treatment Satisfaction Questionnaire for Medication); number, frequency, and duration of 
infectious events and adverse effects were recorded.
Eighty-two patients switched to Hizentra®: 19 (23.2%) from IVIG and 63 (76.8%) from Vivaglobin®. The mean interval 
between infusions was not affected by the shift (7.0 ± 2.0 days with previous treatment versus 7.1 ± 1.2 during Hizentra®). 
A decrease in the number of infusion sites with Hizentra® was recorded in 12 out of 56 patients for whom these data 
were available. At 6 months, 89.7% of patients were satisfied with Hizentra®; no difference in terms of effectiveness, 
side effects, convenience, and global satisfaction was observed. No difference in the incidence of adverse events was 
reported.
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Introduction
In adults and children with primary immunodefi-
ciencies (PID), replacement therapy with immuno-
globulins is required in order to reduce risk of 
infections.1 Lifelong immunoglobulin (IgG) replace-
ment therapy represents the only effective treatment 
for these patients, and is thus the gold standard ther-
apy in the management of PID. It also prolongs sur-
vival, reduces morbidity, and exerts a positive effect 
on patients’ quality of life.2,3 Although intravenous 
administration of IgG (IVIG) has been the therapy 
of choice and it has been widely used for many 
years, subcutaneous administration of IgG (SCIG) 
has recently gained considerable attention among 
patients and physicians.4 SCIG infusions were 
shown to be efficacious, and they can also be self-
administered at home.5,6 Few systemic adverse reac-
tions have been reported, indicating a favorable 
safety profile compared with IVIGs.5,7,8 The average 
serum levels of Ig are comparable to those obtained 
during IVIG therapy, but with reduced oscillations 
between consecutive infusions.6,9,10 With recent 
technical advances in IgG formulation, pure 
and highly concentrated SCIG preparations that 
have relatively low viscosity, and can therefore be 
infused more rapidly, have been developed and are 
increasingly used worldwide.11–13 The potential 
improvement in quality of life in patients switching 
from inpatient-based IVIG therapy to home-based 
SCIG therapy is another important aspect of this 
treatment. The aim of this prospective, observational 
study—conducted in a field-practice scenario—was 
to monitor frequency and number of infusions vari-
ations, the tolerability, and the degree of patient sat-
isfaction following the use of Hizentra® (IgPro20, 
CSL Behring GmbH, Berne, Switzerland), a new 
immunoglobulin preparation for subcutaneous 




This was an observational, prospective multi-cen-
tric open-label study, with retrospective compari-
son. The study was conducted in 15 Italian centers 
(see Appendix).
All centers followed pediatric and/or adult 
patients with PID. The prospective observation 
lasted 6 months: every patient was monitored start-
ing from the signing of the informed consent form. 
Data were collected from 1 August 2012 to 9 
January 2014. Local Institutional Review Board/
Ethics Committee approval was obtained by all 
participating centers. Informed consent was 
obtained from all patients as appropriate.
Patients
The study included patients of any age and gender 
suffering from PID (according to European Society 
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for Immunodeficiencies criteria14 in regular 
replacement treatment with immunoglobulins. In 
more details, patients treated with Vivaglobin® 
(CSL Behring, Berne, Switzerland), which has 
been replaced on the market by Hizentra® since 
November 2011, who were about to switch or had 
already switched to Hizentra®, and patients for-
merly treated with IVIG who have been switched 
to Hizentra® for at least 3 months could be included. 
In patients enrolled from previous IVIG treatment, 
only the latter criteria had to be met; they were ana-
lyzed in a separated subgroup.
Exclusion criteria were as follows: patients par-
ticipating in other experimental studies; those who 
had been included in other clinical studies and who 
received the last dose of experimental drug <2 
months before enrolment (or before a longer period 
if a longer effect of the experimental drug is 
expected); participants carrying HIV, HBV, or HCV 
infection; patients with non-collaborative attitude or 
unable to perform auto-injection of Ig (related only 
to adult patients); pregnant women; and patients who 
cannot complete the planned 6-month follow-up.
Treatment
In line with the field-practice nature of the study, in 
patients who were about to switch from Vivaglobin® 
to Hizentra®, the scheduling of switch was decided 
by the treating physician. In addition, drug dosage, 
interval between infusions, and duration of each 
infusion was also decided by the treating physi-
cian. Treatment adjustment in frequency of admin-
istrations, sites of injections, and infusion length 
were recorded.
SCIG was infused using an SC needle under the 
skin via infusion pump. The SCIG product was 
allowed to reach room temperature prior to infu-
sion. The skin sites were cleansed prior to needle 
insertion with an antiseptic (e.g. alcohol). The nee-
dle was placed at a 90° angle to the skin and inserted 
through the dermal layer. After insertion patients 
and/or their caregiver were advised to gently pull 
back on the syringe plunger and examine the tubing 
for any blood return. If the needle placement was 
correct, the same procedure was repeated for the 
other sites and the infusion pump was turned on.15
Evaluations and outcomes
Over the 6-month study period, three evaluations 
were performed: visit 1 at enrolment (V1), then 
after 3 months (V3), and at the end of the observa-
tion period (V6).
The research hypothesis was based on the data 
gathered from phase III studies16,17 conducted on 
this indication, as well as on the clinical experience 
of the Members of the Scientific Board. The fol-
lowing represented the primary objective of the 
analysis: variations in frequency of Ig infusions 
and number of infusion sites associated with the 
use of Hizentra® compared to those from the same 
monthly interval of the previous year with the for-
mer treatment.
Secondary objectives were as follows:
(1) evaluation of advantages and disadvantages 
of Hizentra®, as reported by patients com-
pared with the previously used Ig formula-
tion (using a TSQM questionnaire;18 in 
detail, patients expressed about 11 items and 
four main areas were evaluated: drug effec-
tiveness; side effects; convenience; and 
global satisfaction. These data were also 
assembled in four points to obtain a 0–100 
score: effectiveness [items 1 and 2]; side 
effects [items 4–6]; convenience [items 7–9]; 
and global satisfaction [items 10 and 11]);
(2) evaluation of number, frequency, and length 
of single infectious episodes;
(3) the comparison of tolerability of Hizentra® 
in this field-practice scenario with results 
obtained in phase III studies (SBI <1; other 
infections <5.18%/year/patient; local reac-
tion <50% of patients).16,17
The following variables were analyzed at every 
visit:
•• Comparison of trough serum IgG levels
•• Variations of the TSQM results
•• Change in the health conditions reported in 
patient’s diary or observed in the clinical 
and/or laboratory parameters during the 
monitoring visits
•• Incidence of systemic adverse reactions and 
their classification by severity during the 
treatment with Hizentra®
•• Incidence and trend of local adverse reac-
tions at the infusion site during Hizentra®
•• Other treatment-related signs and symptoms
•• Laboratory investigations and diagnostic tests 
significant for the primary endpoint and com-
monly performed in the normal diagnostic 
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and therapeutic practice (e.g. total level of 
serum IgG)
•• Number of days on antibiotic therapy
Statistical analysis
Data obtained from case report forms were ana-
lyzed by descriptive statistics. χ2 or Fisher’s exact 
probabilities tests were used to assess group differ-
ences in categorical variables. Odd ratios (OR) and 
95% confidence limits (CL), when possible as all 
values were different from zero, were calculated. 
For continuous variables, the t-test was used with 
logarithmic transformation of non-normal distrib-
uted variables. Two tailed P values were used and 
P values <0.05 were considered statistically sig-
nificant. Data were processed with the SPSSX 
(SPSS 11.0) statistical package (SPSS Inc., 
Chicago, IL, USA).
Results
Study populations and treatment
In total, 82 patients were enrolled. For 76/82 
patients, gender, age, and ethnicity were known. 
All patients were Caucasian, 34/76 (44.7%) were 
female and 42/76 (53.3%) were male. Fifteen 
patients were of pediatric age (median age, 13 
years; interquartile [IQ] range, 11–15 years); the 
median age in the remaining 61 patients was 40 
years (age range, 19–71 years).
Data regarding replacement Ig therapy were 
known for all the 82 patients included. Nineteen 
patients (23.2%) had been using IVIG, while the 
remaining 63 (76.8%) had been using SCIG 
(Vivaglobin®).
Underlying PID was known for 76/82 patients: 
it was a common variable immunodeficiency in 
53/76 (69.7%), X-linked agammaglobulinemia in 
8/76 (10.5%), autosomal recessive agammaglobu-
linemia in 2/76 (2.6%); the remaining 13 patients 
(17.1%) were affected by other types of PID, 
including severe combined immunodeficiency. 
Disease duration was known in 74/82 patients; 
median disease duration was 8.5 years (range, 1–41 
years; IQ range, 4–16 years). Of the 92 patients, 
eight patients (9.8%) dropped out of the study. 
Reasons for drop-outs were transfer of the patient 
to other center or abroad in some cases, unspeci-
fied personal reasons in other cases.
Dose adjustments: Difference between the pre-
study and the study period
Information regarding dosage of infused Ig was 
available for 70/82 patients. In 11/70 patients, the 
same monthly dosage was maintained after treat-
ment switch, with no difference between the pre-
study and the study period. In those patients, the 
mean level of serum IgG was not different in V6 
when compared to V1 (V1: 894 ± 186 mg/dl; V6: 
865 ± 184 mg/dl). In 22 patients, the dosage was 
decreased during the study compared with the pre-
switching period. The mean reduction was –2.97 ± 
3.24 g/month (median, –1.6 g/month; range, 0.8–
14 g/month). In those patients, the mean level of 
serum IgG did not differ between V1 and V6 (850 
± 164 mg/dl versus 853 ± 134 mg/dl). In 39 patients, 
the dosage was increased during the study, with a 
mean increase of 5.18 ± 4.68 g/month (median, 4 
g/month; range, 0.8–19 g/month). Also in those 
patients, no differences in the mean level of serum 
IgG between V1 and V6 were disclosed (817 ± 153 
mg/dl versus 825 ± 176 mg/dl).
In order to evaluate whether the choice to 
increase or decrease the dosage of infused Ig was 
dependent by the serum IgG levels in the pre-study 
period, mean serum IgG level at V1 was evaluated 
in patients who received an increased dosage dur-
ing the study (869.3 ± 164.1 mg/dl) and in patients 
who received a decreased dosage during the study 
(814.6 ± 151.6 mg/dl). No differences in IgG levels 
at V1 between the two groups were found.
Interval between infusions in the pre-study and 
study period
With the aim to verify whether the difference in 
IgG concentration in Hizentra® compared with 
Vivaglobin® could result in modification in inter-
vals between infusions or in the number of infusion 
sites, we evaluated the subgroup of patients (n = 
63) who were already on SCIG in the pre-study 
period. Data regarding interval between infusions 
and number of infusion sites per session were 
available for 56/63 patients.
The mean interval between infusions in the 
pre-study period was 7 ± 2 days, while during the 
study it was 7 ± 1 days. This interval was increased 
in 8/56, decreased in 6/56, and unchanged in 
42/56 patients. Forty-one out of 56 participants 
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had an interval between infusion of 7 days in the 
pre-study period; the number of participants 
which had such interval increased to 43/56 in the 
study period. Among those 43 patients, 36/43 had 
continued with the same interval used in the pre-
study period, five of them had prolonged the 
interval (2 patients from 3 to 7, 1 patient from 5 to 
7, 2 patients from 6 to 7) and two patients had 
reduced the interval between infusion (from 15 
and from 8 days, respectively). In the pre-switch 
period, 9/56 patients received infusions with an 
interval of time <7 days; during the study period 
the patients who received infusions with an inter-
val <7 days were 7/56. Among those seven 
patients, 3/7 had continued with the same interval 
used in the pre-switch period (4, 5, and 6 days, 
respectively), one of them had increased the inter-
val from 2 to 6 days, two patients had reduced the 
interval between infusion from 7 to 5 days and 
one patient had reduced the interval between infu-
sion from 7 to 4 days. Six patients had reduced the 
interval between infusions totally. Among those 
patients, 3/6 also had a reduction in the number of 
infusion sites (from 4 to 2, from 3 to 2, from 2 to 
1, respectively), while in 3/6 the number of sites 
remain unchanged (1, 1, and 2, respectively). 
Nevertheless, those patients who reduced both 
variables did not maintain the same dosage at the 
shift from Vivaglobin® to Hizentra®. An increase 
in the number of infusions sites was recorded in 
two patients, a decrease was recorded in 12 
patients and no variation was recorded in 42 
patients. Both patients who had an increase (from 
1 to 2 sites) showed a longer interval between 
infusion and did not require any variation of 
monthly dosage. For that reason, the amount of 
product per session increased together with the 
number of infusion. Among 12 patients who had a 
decrease and maintained the same monthly dos-
age, one patient reported a decrease in interval 
between infusions, too. The number of patients 
who experienced reduction in the number of sites 
was sixfold than the number of patients with 
increased number of sites (Figs. 1 and 2).
IgG levels
The levels of serum IgG at V1 was recorded in 
51/82 patients. The mean serum level of IgG was 
841 ± 157 mg/dl (range, 604–1110 mg/dl). At V3, 
IgG levels were evaluated in 47/82 patients; the 
mean IgG level was 817 ± 151 mg/dl (range, 580–
1320 mg/dl). At V6, IgG levels were evaluated in 
51/82 patients; the mean IgG level was 840 ± 166 
mg/dl (range, 631–1280 mg/dl).
In 35/82 patients, IgG levels have been meas-
ured at all visits (V1, V3, and V6). No differences 
between IgG levels between V3 and V6 were dis-
closed (Table 1).
Fig. 1. Differences* in the interval (number of days) 
between infusion in the pre-study (V1) and study period (V6). 
*Differences correspond to the number of days between 
infusions in the pre-study period less the number of days 
between infusions in the study period. Positive values indicate 
increased intervals, negative values indicate decreases intervals. 
Zero indicates no variation.
Fig. 2. Differences* in the number of infusion sites in the 
pre-study (V1) and study period (V6). *Differences correspond 
to the number of infusion sites in the study period less the 
number of infusion sites in the pre-study period. Positive values 
indicate an increase in the number of sites, negative values 
indicate a decrease in the number of sites. Zero indicates no 
variation.
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Advantages and disadvantages of Hizentra®: 
Results from the TSQM questionnaire
The questionnaire was presented to all 82 patients: 
a mean of 86.4% answered questions at V1, except 
for items number 4, 5, and 6, that were filled only 
from 38.7% of patients meanly. At V2, a mean of 
62.9% completed the questionnaire, but the mean 
was lower for the items 4, 5, and 6 (39.7%). The 
number of answered questions decreased at V6, 
when 46.1% of patients completed the form 
meanly, and the percentage was even less for items 
4, 5, and 6 (19%).
At V1, 87.3% were satisfied about therapy and 
63.4% were very satisfied. At V3 and V6, 84.6% 
and 89.7% were satisfied, respectively, and after 6 
months the number of unsatisfied patients was 
even lower.
Most patients were satisfied with symptoms pal-
liation at V1 (85.9%) and this percentage increased 
at V6 (94.5%).
Regarding the influence of side effects on physi-
cal state, at V1 40% of patients were unsatisfied. 
This percentage slightly increased at V3 (42.9%) 
and even more at V6 (56.1%). Similar results were 
reported about the influence of side effects on 
mental state: the number of unsatisfied patients 
increased during the study period, from 21.5% to 
38.5%. On the other hand, the number of patients 
unsatisfied from influence of SCIG therapy on 
emotional sphere remained almost unchanged and 
lower than 50% all over the study period.
The number of patients that were satisfied from 
how the product is easy to use was around 70% 
with negligible variations over the 6-month follow-
up. Moreover, the percentage of very satisfied 
patients increased from 14.3% to 21% during the 
observation period. Regarding the scheduling of 
SCIG, most patients were satisfied at V1 (81.4%) 
and the percentage was even higher at V6 (86.8%). 
Similar findings were obtained for the frequency of 
infusions, with an increase of satisfied patients 
from 65.7% to 71.1%. The rate of satisfaction 
about the balance between advantages and disad-
vantages did not change during the study period, 
remaining >90%.
Global satisfaction about therapy was 90% at V1 
and slightly higher at V6 (94.5%) (Tables 2 and 3).
Safety considerations
Infections were reported in the clinical history of 
seven patients at V1, in 22 participants at V3, and 
in 24 patients at V6. Autoimmune diseases were 
reported in the clinical history of four patients at 
V1, three patients at V3, and no patients at V6.
Data on tolerability in the pre-switch period 
were available for 76 patients. Among them 69/76 
(90.8%) reported a good tolerability; 6/76 (7.9%) 
reported rare minor systemic adverse events, and 
1/76 (1.3%) reported frequent minor systemic 
adverse events. As for the local adverse events, 
16/76 (21%) reported swelling, 7/76 (9.2%) expe-
rienced pain, 36/76 (47.4%) reported redness, and 
11/76 (14.4%) had itching. Overall, side effects 
were reported by 11.3% of patients at V1, by 17.3% 
at V3, and by 13.5% at V6.
During the study period, pain was never reported 
by 66/76 patients (86.4%). Overall, pain was 
reported in 65/246 infusions in the 10 patients 
experiencing pain (26.4%). Taking all infusions 
and all patients, pain was reported in <5% of 
infusions.
Swelling was never reported by 49/76 patients 
during the study period (64.4%) and it was reported 
by 27/76 patients with a range of 1/26 (4.8%) infu-
sions and 26/26 (100%) infusions. Among the 63 
patients who were already on SCIG before switch-
ing, five lacked safety data prior to study inclusion. 
The analysis of local adverse events was therefore 
performed on 58 patients. In the pre-study period, 
15/58 patients had reported swelling: among them 
7/15 also had swelling in the study period. Of these 
seven patients who reported swelling with 
Hizentra®, the symptom was not reported at all 
infusions, but with its occurrence range of 7.7–
100% of infusions. Three out of these seven patients 
reported swelling at all infusions. Among the 43 
patients who had not reported swelling with 
Vivaglobin®, 31/43 had no swelling using Hizentra®; 
in the 12 patients who did not report swelling with 
Vivaglobin® but reported swelling with Hizentra®, 
the symptom was not present at all infusions, but 
with a range of 3.8–100%. Eight out of these 12 
Table 1. IgG levels at different timepoints.
Patients (n) Serum IgG levels (mg/dl)
 Mean SD Range
Enrollment (V1) 51 841 157 604–1110
III month (V3) 47 817 151 580–1320
VI month (V6) 51 840 166 631–1280
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patients reported swelling at all infusions. Overall 
236/307 (77.4%) infusions in the 12 patients were 
associated with swelling. The difference between 
swelling incidence in the pre-study and study period 
was not statistically different.
Overall, 7/58 (12.1%) patients reported pain in 
the pre-study period: among them, 2/7 reported 
pain in the study period in at least one infusion. 
Pain was not present at all infusions, but in 1/26 
infusion in one patient and in 13/26 infusions in the 
other. Among the 51 patients who had not reported 
pain with Vivaglobin®, 44/51 (86.3%) had no pain 
either using Hizentra® while 7/51 (13.7%) reported 
pain in at least one infusion. The symptom was not 
present at all infusions, but with a range of 7.4–
96.2% of infusions. Overall 75/222 (33.8%) infu-
sions in the seven patients were associated with 
pain. The difference between pain incidence in the 
pre-study and study period was not statistically 
different.
In total, 32/58 patients had reported redness in 
the pre-study period. Among them, 12/32 had red-
ness also during the study period. This symptom 
was not reported at all infusions, but with a range 
of 4.0–100% of infusions (overall: 145/310, 
46.8%). Only 1/12 patient reported redness at all 
infusions. Among the 26 patients who had not 
reported redness with Vivaglobin®, 22 did not 
experience redness on Hizentra® treatment; in the 
remaining four patients, redness was not present at 
all infusions, but with a range of 4.3–96.2%. 
Overall, 51/87 (58.6%) infusions in the four 
patients were associated with redness. The differ-
ence between redness incidence in the pre-study 
and study period did not reach statistical 
significance.
With respect to itching, 11/58 patients reported 
this symptom with Vivaglobin®; among them, 2/11 
experienced itching also with Hizentra®. Itching 
was not present at all infusions but in 5/26 (19.2%) 
infusions in one patient and in 7/24 (29.2%) in the 
other patient. Among the 47 patients who did not 
reported itching with Vivaglobin®, 41/47 had no 
itching either using Hizentra; when reported, itch-
ing was not present at all infusion but with a range 
between 1/27 (3.7%) and 13/26 (50.0%). In the six 
patients who reported itching, this symptom was 
present in 28 out 142 infusions (19.7%). No differ-
ences in the incidence of itching incidence between 
the pre-study and study period were disclosed.
In total, 19/58 patients had reported other 
unspecified symptoms with Vivaglobin®: among 
them, none reported other unspecified symptoms 
with Hizentra®. Among the 39 patients who had 
not reported unspecified symptoms with 
Vivaglobin®, 37 had no unspecified symptoms also 
Table 2. TSQM questionnaire, effectiveness, and side effects: number of respondents and score (mean, median, SD, range).
Effectiveness Side effects
 V1 V3 V6 V1 V3 V6
Respondents (n) 71 52 38 32 33 14
Score Mean* 72.5 68.2 73.9 87.8 85.7 78.0
Median 83.3 66.6 75.0 100.0 95.8 85.4
SD 23.7 24.6 18.8 16.7 25.2 27.4
Range 0–100 0–100 8.3–100 41.7–100 8.3–100
* No differences in the mean score attributed to “effectiveness” or “side effects” between V1 and V6 were found.
Table 3. TSQM questionnaire, convenience, and global satisfaction: number of respondents and score (mean, median, SD, range).
Convenience Global satisfaction
 V1 V3 V6 V1 V3 V6
Respondents (n) 70 51 38 70 51 37
Score Mean* 68.6 70.2 69.3 77.3 73.4 75.7
Median 72.2 72.2 72.2 83.3 75.0 75.0
SD 19.8 19.4 21.1 19.4 23.0 17.1
Range 16.67–100 0–100 5.56–100 0–100 0–100 16.67–100
* No statistically significant differences in the mean score attributed to “convenience” or “global satisfaction” in V1 and V6 were found.
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using Hizentra®; in the two patients who reported 
symptoms with Hizentra®, the symptoms were not 
present at all infusions, but at 1/26 (4.3%) in one 
patient and at 4/26 (96.2%) in the other. The differ-
ence between the two treatments was not 
significant.
Data regarding school or work days lost due to 
PID at each visit was available for 73/82 patients. 
Mean days lost at V1 was 4 ± 12 days, 1 ± 2 days 
at V3, and 1 ± 3 days at V6. The difference between 
V3/6 versus V1 was significant (P = 0.0158 and 
P = 0.0318, respectively). Since data in V1 were 
referred to the previous 12 months while data in V3 
and V6 were referred to a 3-month interval, the 
comparison was recalculated using for V1 a pro-
jection of the data to a trimester. Using that esti-
mate, no difference was found between the baseline 
and the two following visits (P = 0.2347 for V3 
versus V1 and P =0.7723 for V6 versus V1, 
respectively).
Discussion
Unlike the expectations, this study suggests that 
in clinical practice Hizentra® has been introduced 
in substitution of other products without varia-
tions in the interval between infusions; and among 
patients in whom intervals were modified, more 
patients had an increase rather than a decrease. 
The choice to maintain patients on an interval 
between infusions of about 7 days suggests that 
physicians consider this time span as the best 
interval to guarantee a stable level of serum IgG 
over time.
Although the small number of patients did not 
allow to reach statistical significance, an increased 
number of sites was reported only in two patients, 
while 12 participants did not experience changes in 
this parameter. Together, data show that reduction 
in the number of sites is preferred over shorter 
intervals between infusions. Differing from inter-
val between infusions, the number of sites does not 
interfere with drug effectiveness, but can influence 
only logistic issues. Moreover, it may result in 
fewer side effects in the absence of any effect on 
drug effectiveness. Data from the TSQM question-
naire showed no difference in effectiveness, side 
effects, convenience, and global satisfaction for 
the study period compared with the pre-study 
period. When patients who were in IVIG therapy in 
the pre-study period were separately analyzed, the 
results did not change as well. IgG preparation for 
subcutaneous administration is confirmed to be 
safe, easy to use, and well-tolerated by patients. 
Overall, about half of the patients were not satis-
fied with at least one item; in particular, influence 
of therapy on daily life. Nevertheless, only one-
third of those unsatisfied patients clearly experi-
enced some side effects. Dissatisfaction seemed to 
correlate more with occurrence of infective epi-
sodes despite therapy, with loss of school or work 
days. However, none of the unsatisfied patients 
was hospitalized. Nevertheless, and despite the 
number of answers decreasing over time, the 
majority of patients, both those already using SCIG 
and those using IVIG in the pre-study, have 
reported satisfaction for IgG therapy with a global 
satisfaction score over 75%. The shift from previ-
ous therapy to Hizentra® was not associated with 
changes in serum IgG, independent of the previ-
ously used treatment (IVIG or SCIG). Such data 
confirm that the more concentrated product retains 
the same efficacy as the previous one. Finally, side 
effects have been evaluated, overall showing no 
difference between Hizentra® and previous IgG 
used. The obtained data are comparable with the 
results of the study of Niebur et al.19 about transi-
tion from Vivaglobin to Hizentra. Different from 
ours, the authors made a direct comparison of the 
pharmacokinetics and efficacy of the two products, 
showing that these are similar. Although it was a 
monocentric study involving a smaller cohort of 
participants with primary antibody deficiency, 
results on safety and treatment satisfaction are 
comparable. In fact, they showed that Hizentra was 
considered more favorably than Vivaglobin in the 
domain of side effects but that, overall, the two 
products are similar.
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List of centers participating in the study and clinical 
research coordinators (indicated in parentheses)
•• SOD Immunoallergologia, AOU- Policlinico 
Careggi, Florence, Italy (A. Matucci)
•• U.O.C. Pediatria Generale e Specialistica 
“Federico Vecchio”, Università degli Studi, 
Policlinico- Giovanni XXIII, Bari, Italy (B. 
Martire)
•• Azienda Ospedaliera Spedali Civili di 
Brescia, Brescia, Italy (A. Plebani)
•• Clinica Pediatrica II AOU Meyer, Florence, 
Italy (C. Azzari)
•• Dipartimento di Medicina Interna CISI 
Azienda Ospedaliera Universitaria “Federico 
II” Napoli, Naples, Italy (G. Spadaro)
•• Unità Operativa di Oncoematologia 
Pediatrica Ospedale CIVICO, Palermo, Italy 
(A. Trizzino)
•• Centro di Riferimento Immunodeficienze 
Primitive Azienda Policlinico Umberto I, 
Rome, Italy (I. Quinti)
•• UOC di Immunoinfettivologia Ospedale 
Pediatrico Bambino Gesù, Rome, Italy (A. 
Finocchi)
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•• Centro Interdisciplinare di Pediatria. Rome, 
Italy (V. Moschese)
•• Struttura Semplice di Immuno-Reumatologia 
Ospedale Regina Margherita, Turin, Italy (S. 
Martino)
•• Medicina generale Ospedale Torrette, 
Ancona, Italy (M.G. Danieli)
•• Dipartimento di Medicina Interna e 
Oncologia Clinica Università degli Studi di 
Bari, Bari, Italy (A. Vacca)
•• Dipartimento di Medicina (DIMED), 
Immunologia Clinica Università di Padova, 
Padua, Italy (C. Agostini),
•• Allergologia ed Immunologia Dipartimento 
di Medicina Interna (pad.8) Azienda 
Ospedaliero-Universitaria Santa Maria della 
Misericordia, Udine, Italy (M. De Carli)
•• Dipartimento di Allergologia Policlinico S. 
Annunziata di Chieti, Chieti, Italy (M. Di 
Gioacchino)
